{
    "ticker": "TNGX",
    "name": "Tango Therapeutics, Inc.",
    "description": "Tango Therapeutics, Inc. is a biotechnology company focused on the discovery and development of novel cancer therapies. Founded in 2017, Tango is at the forefront of precision medicine, leveraging its proprietary gene-editing technology to target specific genetic vulnerabilities in cancer cells. The company's innovative approach aims to develop therapies that are more effective and have fewer side effects than traditional cancer treatments. Tango's lead programs focus on the treatment of various cancers, including those driven by specific genetic mutations. With a strong emphasis on collaboration, Tango partners with leading academic institutions and industry players to advance its research and bring transformative therapies to patients. The company is committed to improving patient outcomes and delivering on the promise of personalized medicine through its cutting-edge science and technology. Tango's mission is to empower patients with cancer by providing them with targeted treatment options that align with their unique genetic profiles.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "2017",
    "website": "https://www.tangotherapeutics.com",
    "ceo": "Barbara Klencke",
    "social_media": {
        "twitter": "https://twitter.com/TangoThera",
        "linkedin": "https://www.linkedin.com/company/tango-therapeutics/"
    },
    "investor_relations": "https://www.tangotherapeutics.com/investors",
    "key_executives": [
        {
            "name": "Barbara Klencke",
            "position": "CEO"
        },
        {
            "name": "Michael W. B. W. G. M. C. M. K. V. C. A.",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Cancer Therapies",
            "products": [
                "Tango's Lead Drug Candidates"
            ]
        }
    ],
    "seo": {
        "meta_title": "Tango Therapeutics, Inc. | Precision Cancer Therapies",
        "meta_description": "Explore Tango Therapeutics, Inc., a leader in precision medicine focused on developing innovative cancer therapies. Learn about our advanced gene-editing technologies and commitment to patient care.",
        "keywords": [
            "Tango Therapeutics",
            "Cancer Therapy",
            "Biotechnology",
            "Precision Medicine",
            "Genetic Vulnerabilities"
        ]
    },
    "faq": [
        {
            "question": "What does Tango Therapeutics specialize in?",
            "answer": "Tango Therapeutics specializes in developing precision cancer therapies using innovative gene-editing technologies."
        },
        {
            "question": "Who is the CEO of Tango Therapeutics?",
            "answer": "Barbara Klencke is the CEO of Tango Therapeutics, Inc."
        },
        {
            "question": "Where is Tango Therapeutics headquartered?",
            "answer": "Tango Therapeutics is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What are the main goals of Tango Therapeutics?",
            "answer": "The main goals of Tango Therapeutics are to improve patient outcomes through targeted cancer treatments and to advance the field of precision medicine."
        },
        {
            "question": "When was Tango Therapeutics founded?",
            "answer": "Tango Therapeutics was founded in 2017."
        }
    ],
    "competitors": [
        "CRSP",
        "EDIT",
        "SGEN",
        "ABCL"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "MRNA",
        "BMY"
    ]
}